Trial Profile

Switching to everolimus versus continuing tacrolimus in renal transplant recipients: the ERIC study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate sodium; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms ERIC

Most Recent Events

04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society 2010.
05 Jul 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com